A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

Inclusion Criteria: * 1\. HBsAg or/and HBV DNA Positive for at least 6 months 2\. HBeAg negative 3\. Received NAs stabilization therapy for at least 2 years 4\. ALT≤ 2×ULN 5\. HBV DNA\< LLQD(lower limit of quantitative detection) in Screening 6\. Serum total bilirubin\<2×ULN 7\. no childbirth plan within 2 years and agree to take effective contraceptive measures throughout the treatment period and within 3 months after the last dose, and that the woman is not pregnant or breastfeeding. 8\. have not participant in another clinical trial within 3 months before screening 9\. Subjects have good compliance with the protocol 10\. Subjects understood and agreed to sign the informed consent form. Exclusion Criteria: * 1\. Contraindications of Peginterferon such as depressive disorder, epilepsy, autoimmune diseases, uncontrolled thyroid dysfunction, etc 2\. Subjects with cirrhosis, e.g., definite cirrhosis on imaging such as abdominal ultrasound and CT; liver biopsy with Metavir fibrosis score = 4; clinical diagnosis of cirrhosis by the investigator. 3\. Decompensated liver disease 4\. Child-Pugh score of B-C or over 6 points. 5\. Subjects with any of the following circumstances * History of decompensated liver disease * History of serious heart disease (including unstable or uncontrolled heart disease within 6 months) * Uncontrolled seizures, severe psychiatric disorders, or a history of psychiatric disorders * with history of organ transplantation * with poorly controlled diabetes and hypertension * with autoimmune diseases, immune-related extrahepatic manifestations, thyroid disease, malignant tumors, or in immunosuppressive therapy * underlying diseases such as malignant tumor, severe infection, heart failure and chronic obstructive pulmonary disease and other serious diseases. * with history of alcohol or drug abuse 6\. Creatinine clearance \<60 mL/min. 7\. HAV, HCV, HDV, HEV or HIV co-infection 8\. Subjects who must be treated with Nucleosides (acids) other than TAF during treatment period 9\. Subjects who used interferon in the 6 months prior to the screening period 10\. Positive for anti-HBV Pre-S1 antibody. 11\. Hemocytopenia: White blood cells \< 3 × 10\^9 / L, neutrophil \< 1.5 × 10\^9 / L, platelet \< 60 × 10\^9 / L, 12\. Female subjects pregnancy test positive 13\. known to be allergic to the investigational drug or the underlying treatment drug 14\. Other laboratories or auxiliary examinations are obviously abnormal